Sanofi’s Efdoralprin Alfa shows superiority in phase 2 Alpha-1 antitrypsin deficiency study

Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy

Glenmark Pharmaceuticals USA to launch Ropivacaine Hydrochloride Injection USP

Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA

Biocon Biologics secures Health Canada nod for biosimilars Yesintek, Yesintek IV

Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients

Pimicotinib delivers lasting tumor responses and sustained symptom relief in TGCT patients

Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile

Bajaj Healthcare posts Q2 FY26 PAT at Rs. 11.10 Cr

Bajaj Healthcare has reported total income of Rs. 149.56 crore during the period ended September 30, 2025

TTK Healthcare reports Q2 FY26 net profit at Rs. 20.38 Cr

TTK Healthcare has reported total income of Rs. 222.58 crore during the period ended September 30, 2025

Cupid achieves CE (EU IVDR) certification for pregnancy and syphilis test kits

Biocon Biologics and Civica launch private-label Insulin glargine

Supriya Lifescience honoured for outstanding export excellence by Govt. of Maharashtra

IOL Chemicals receives EDQM certificate for Pantoprazole Sodium Sesquihydrate Process-III

Pantoprazole sodium is a proton pump inhibitor reduces stomach acid